CMS Finalizes Renal Denervation Coverage
The Centers for Medicare and Medicaid Services (CMS) has issued its final National Coverage Determination (NCD) on renal denervation (RDN), benefiting Medtronic and Recor Medical.
Both companies develop RDN systems, with Recor Medical receiving FDA approval for its Paradise ultrasound RDN system in November 2023, followed by Medtronic's approval for the Symplicity Spyral system.
- Recor Medical received FDA approval for its Paradise ultrasound RDN system in November 2023.
- Medtronic received FDA approval for the Symplicity Spyral system shortly after.
The companies have ongoing patent litigation related to their RDN systems.
In July, both companies welcomed CMS' planned coverage for their technologies when it proposed the NCD for uncontrolled hypertension, anticipating a decision by October.
Author's summary: CMS finalizes renal denervation coverage.
More News
- Etsy Stock Falls 9% As CEO Steps Down
- Israel Responds Powerfully: Standing Strong Against Hamas Threats
- ChatGPT teams up with PayPal to make it easier for you to buy stuff in chat
- Vention Advances Intelligent Manufacturing with Major AI and Developer Platform Expansions at 6th Annual Demo Day
- NBCU, iHeartMedia Agree On 2026 Winter Olympics Partnership | Radio & Television Business Report
- From MRI to Ozempic: breakthroughs that show why fundamental research must be protected
- Step-by-Step Guide To Custom Tax Return Folders - Canyon News
- NVIDIA Stock Soars 3.6% as Company Edges Closer to $5 Trillion Valuation
- iOS 26’s Shortcuts app adds 25+ new actions, here’s everything new - 9to5Mac
- Horoscopes Oct. 29, 2025: Gabrielle Union, it’s time to put yourself first.